Ranibizumab

Lucentis (ranibizumab) is an antibody pharmaceutical. Ranibizumab was first approved as Lucentis on 2006-06-30. It is used to treat diabetic retinopathy, macular edema, and retinal vein occlusion in the USA. It has been approved in Europe to treat degenerative myopia, diabetes complications, diabetic retinopathy, macular edema, and wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A.